Correction
Accepted on 31 Oct 2025
Corrigendum: Cost-effectiveness analysis of cabozantinib plus atezolizumab for advanced hepatocellular carcinoma
in Drugs Outcomes Research and Policies
Correction
Accepted on 31 Oct 2025
in Drugs Outcomes Research and Policies
Original Research
Accepted on 31 Oct 2025
in Public Health and Nutrition
Original Research
Accepted on 31 Oct 2025
in Marine Fisheries, Aquaculture and Living Resources
Original Research
Accepted on 31 Oct 2025
in Power Electronics
Original Research
Accepted on 31 Oct 2025
in Digital Public Health
Systematic Review
Accepted on 31 Oct 2025
in Clinical Nutrition
Original Research
Accepted on 31 Oct 2025
in Environmental Health and Exposome
Original Research
Accepted on 31 Oct 2025
in Biomechanics
Original Research
Accepted on 31 Oct 2025
in Injury Prevention and Control
Systematic Review
Accepted on 31 Oct 2025
in Occupational Health and Safety
Original Research
Accepted on 31 Oct 2025
in Cognition
Original Research
Accepted on 31 Oct 2025
in ELSI in Science and Genetics
Brief Research Report
Accepted on 31 Oct 2025
in Pediatric Ophthalmology and Strabismus
Original Research
Accepted on 31 Oct 2025
in Glaucoma
Review
Accepted on 31 Oct 2025
in Substance Use Disorders and Behavioral Addictions
Original Research
Accepted on 31 Oct 2025
in Respiratory Physiology and Pathophysiology